The histone code and treatments for acute myeloid leukemia

New England Journal of Medicine

Volumn 366, Issue 10, 2012, Pages 960-961

  Godley, Lucy A ^a   Le Beau, Michelle M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; JQ 1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER PROGNOSIS; CHROMATIN STRUCTURE; CHROMOSOME TRANSLOCATION; DNA METHYLATION; DRUG MECHANISM; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC RISK; HISTONE CODE; HISTONE MODIFICATION; HUMAN; LEUKEMOGENESIS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 84857891404     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr1113401     Document Type: Article

References (2)

1. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478:524-8.
2. Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature 2010;468:1067-73.